Side population in the pancreatic cancer cell lines SW1990 and CFPAC-1 is enriched with cancer stem-like cells

Oncology Reports

Volumn 23, Issue 5, 2010, Pages 1375-1382

  Yao, Jie ^a,c   Cai, Hui Hua ^a   Wei, Ji Shu ^a   An, Yong ^a   Ji, Zhen Ling ^b   Lu, Zi Peng ^a   Wu, Jun Li ^a   Chen, Ping ^c   Jiang, Kui Rong ^a   Dai, Cun Cai ^a   Qian, Zhu Yin ^a   Xu, Ze Kuan ^a   Miao, Yi ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

^c YANGZHOU UNIVERSITY   (China)

Author keywords

Cancer stem cell; Chemotherapy resistance; Pancreatic cancer; Self renewal; Side population; Tumorigenesis

Indexed keywords

GEMCITABINE; LIPOCORTIN 5;

ARTICLE; CANCER STEM CELL; CARCINOGENESIS; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL POPULATION; CONTROLLED STUDY; DRUG SENSITIVITY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PANCREAS CANCER; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD24; ANTIGENS, CD44; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; PEPTIDES; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77950801062     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000774     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet 363: 1049-1057, 2004.
3. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
4. Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G and Blatter J: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73: 101-105, 1996. (Pubitemid 26026268)
5. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003. (Pubitemid 36418143)
6. Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumour initiating cells. Nature 432: 396-401, 2004.
7. Collins AT, Berry PA, Hyde C, Stower MJ and Maitland NJ: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 55: 10946-10951, 2005.
8. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C and DeMaria R: Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115, 2007.
9. Li C, Heidt DG, Dalerba P, et al: Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037, 2007.
10. Kazumasa F, Yoshiro S, Masaki O, et al: Tumor initiating potential of side population cells in human gastric cancer. Int J Oncol 34: 1201-1207, 2009.
11. Hermann PC, Huber SL, Herrler T, et al: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323, 2007.
12. Goodell MA, Brose K, Paradis G, Conner AS and Mulligan RC: Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183: 1797-1806, 1996.
13. Hirschmann-Jax C, Foster AE, Wulf GG, et al: A distinct 'side population' of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101: 14228-14233, 2004.
14. Kondo T, Setoguchi T and Taga T: Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 101: 781-786, 2004.
15. Chiba T, Kita K, Zheng YW, et al: Side population purified from hepatocellular carcinoma cells harbors cancer stem celllike properties. Hepatology 44: 240-251, 2006.
16. Ho MM, Ng AV, Lam S and Hung JY: Side population in human lung cancer cell lines and tumors is enriched with stemlike cancer cells. Cancer Res 67: 4827-4833, 2007.
17. Haraguchi N, Inoue H, Tanaka F, Mimori K, Utsunomiya T, Sasaki A and Mori M: Cancer stem cells in human gastrointestinal cancers. Hum Cell 19: 24-29, 2006.
18. Mitsutake N, Iwao A, Nagai K, Namba H, Ohtsuru A, Saenko V and Yamashita S: Characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively. Endocrinology 148: 1797-1803, 2007.
19. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, et al: Ovarian cancer side population defines cells with stem cell like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 103: 11154-11159, 2006.
20. Zhou J, Wang CY, Liu T, et al: Persistence of side population cells with high drug efflux capacity in pancreatic cancer. World J Gastroenterol 14: 925-930, 2008.
21. Kabashima A, Higuchi H, Takaishi H, et al: Side population of pancreatic cancer cells predominates in TGF-beta-mediated epithelial to mesenchymal transition and invasion. Int J Cancer 124: 2771-2779, 2009.
22. Feuerhake F, Sigg W, Höfter EA, Dimpfl T and Welsch U: Immunohistochemical analysis of Bcl-2 and Bax expression in relation to cell turnover and epithelial differentiation markers in the non-lactating human mammary gland epithelium. Cell Tissue Res 299: 47-58, 2000.
23. Chen W, Wang GM and Liu YJ: Apoptosis resistance can be used in screening the markers of cancer stem cells. Med Hypotheses 67: 1381-1383. 2006.
24. Li HZ, Yi TB and Wu ZY: Suspension culture combined with anticancer regimens for screening breast cancer stem cells. Med Hypotheses 68: 988-990, 2007.
25. Zhou S, Schuetz JD, Bunting KD, et al: The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side population phenotype. Nat Med 7: 1028-1034, 2001.
26. Bunting KD: ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells 20: 11-20, 2002.
27. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
28. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU and Gallick GE: Development and characterization of gemcitabineresistant pancreatic tumor cells. Ann Surg Oncol 14: 3629-3637, 2007.
29. Liau SS, Ashley SW and Whang EE: Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma. J Gastrointest Surg 10: 1254-1262, 2006.
30. Liau SS and Whang E: HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Clin Cancer Res 14: 1470-1477, 2008.
31. Mogi M, Yang J, Lambert JF, et al: Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J Biol Chem 278: 39068-39075, 2003.
32. Hu C, Li H, Li J, et al: Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis 29: 2289-2297, 2008.
33. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW and Holland EC: PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4: 226-235, 2009.
34. Yu C, Zhang X, Sun G, et al: RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells. J Cell Mol Med 12: 2334-2349, 2008.